Balixafortide is the most advanced and only CXCR4 antagonist in development in a pivotal Oncology global registration trial. Polyphor today announced the enrollment of the first patient in its FORTRESS clinical trial, the pivotal Phase III study evaluating...
Sanofi and Regeneron announce positive topline Phase 2 results for IL-33 antibody in asthma REGN3500 (SAR440340) monotherapy significantly reduced loss of asthma control and improved lung function compared to placebo PARIS and TARRYTOWN, NY – June 21, 2019 – Sanofi...
Data selected for oral presentation during a plenary session at AACR’s Immune Cell Therapies for Cancer: Successes and Challenges of CAR T Cells and Other Forms of Adoptive Therapy Conference Company to host investor event and webcast on Monday, July 22 Marker...
Achieve Life Sciences, Inc. (Nasdaq: ACHV), a clinical-stage pharmaceutical company focused on nicotine addiction, today announced that an abstract featuring data from the Phase 2b ORCA-1 trial has been accepted for oral presentation at the SRNT-E Annual Conference,...
– Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing novel drugs to address treatment resistance, today announced initiation of the registrational Phase 2 portion of its TRIDENT-1 clinical study of patients with ROS1+...
Email
Text